Search for: "Mylan Pharmaceuticals"
Results 201 - 220
of 739
Sort by Relevance
|
Sort by Date
3 Jan 2018, 5:10 am
On the heels of the Ericsson decision, further briefing on the waiver issue was recently authorized in Mylan Pharmaceuticals Inc., et al. v. [read post]
26 Dec 2017, 7:08 pm
Mylan paid approximately $231.7 million to the federal government and $213.9 million to state Medicaid programs. [read post]
5 Dec 2017, 7:40 am
Here are the amici curiae in the matter of Mylan Pharmaceuticals Inc. et al v. [read post]
1 Dec 2017, 2:53 pm
Stark in Javelin Pharmaceuticals, Inc. et al. v. [read post]
30 Nov 2017, 5:26 am
Here is the amicus brief filed in Mylan Pharmaceuticals Inc. v. [read post]
7 Nov 2017, 11:04 am
Here is the order in Mylan Pharmaceuticals v. [read post]
5 Nov 2017, 3:10 pm
In Novartis AG v Generics (UK) Ltd (trading as Mylan) [2012] [read post]
1 Nov 2017, 2:58 pm
See also, 16-712bsacAAM; and 16-712 bsac America’s Health Insurance Plans; 16-712 bsac Mylan Pharmaceuticals Inc_ (“Mylan’s experiences with inter partes review highlight the pro-competitive nature of inter partes review. [read post]
1 Nov 2017, 9:49 am
And interest is not limited to the pharmaceutical sector. [read post]
19 Oct 2017, 10:29 am
” Generic drug manufacturers Teva Pharmaceuticals USA, Inc.; Akorn, Inc.; Mylan, Inc.; and Mylan Pharmaceuticals, Inc., that wish to manufacture and sell bioequivalent drugs having the same components as Restasis challenged that the patents asserted by Allergan are invalid in defense to a patent infringement suit filed by Allergan. [read post]
19 Oct 2017, 10:29 am
” Generic drug manufacturers Teva Pharmaceuticals USA, Inc.; Akorn, Inc.; Mylan, Inc.; and Mylan Pharmaceuticals, Inc., that wish to manufacture and sell bioequivalent drugs having the same components as Restasis challenged that the patents asserted by Allergan are invalid in defense to a patent infringement suit filed by Allergan. [read post]
25 Sep 2017, 3:59 am
Here is the brief in the matter captioned Mylan Pharmaceuticals Inc. v. [read post]
20 Sep 2017, 9:18 am
Mylan Pharmaceuticals Inc., a patent infringement matter brought under the Hatch-Waxman statute and filed before the TC Heartland decision, the parties did not dispute that, in light of TC Heartland, the defendant, a West Virginia corporation, could not be said to “reside” in Delaware. [read post]
13 Sep 2017, 7:44 am
Mylan Pharmaceuticals, Inc., 1-17-cv-00379 (DED September 11, 2017, Order) (Stark, USDJ) [read post]
5 Sep 2017, 7:45 am
According to DOJ’s press release: Pharmaceutical companies Mylan Inc. and Mylan Specialty L.P. have agreed to pay $465 million to resolve claims that they violated the False Claims Act by knowingly misclassifying EpiPen as a generic drug to avoid paying rebates owed primarily to Medicaid, the Justice Department announced today. [read post]
25 Aug 2017, 2:25 pm
(collectively, “Mylan”) have… The post Pharmaceutical Companies Agree to Pay $465 Million Settlement in EpiPen False Claims Act Lawsuit appeared first on TZ Legal - Fraud Fighters. [read post]
25 Aug 2017, 7:02 am
The Medicaid drug rebate requirements that Mylan allegedly sought to avoid were enacted by Congress to prevent drug manufacturers from gouging state Medicaid programs on prices for pharmaceuticals that are only available from a single source. [read post]
25 Aug 2017, 7:02 am
The Medicaid drug rebate requirements that Mylan allegedly sought to avoid were enacted by Congress to prevent drug manufacturers from gouging state Medicaid programs on prices for pharmaceuticals that are only available from a single source. [read post]
20 Aug 2017, 7:14 am
Pharmaceutical companies Mylan Inc. and Mylan Specialty L.P. agree to pay $465 million to settle a lawsuit brought under the False Claims Act (FCA). [read post]
